Cargando…

The Role of CYP2D6 Polymorphisms in Determining Response to Tamoxifen in Metastatic Breast Cancer Patients: Review and Egyptian Experience

BACKGROUND: Metastatic breast cancer (MBC) represents a major health problem in Egypt and worldwide. Prognostic and predictive factors for patients with MBC are highly required for better management and improved survival. The aim of this study was to assess the prognostic and predictive value(s) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Malash, Ibrahim, Mansour, Osman, Shaarawy, Sabry, Abdellateif, Mona S, Omar, Anan, Gaafar, Rabab, Zekri, Abdel-Rahman N, Ahmed, Ola S, Bahnassy, Abeer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046328/
https://www.ncbi.nlm.nih.gov/pubmed/33369460
http://dx.doi.org/10.31557/APJCP.2020.21.12.3619
_version_ 1783678826127032320
author Malash, Ibrahim
Mansour, Osman
Shaarawy, Sabry
Abdellateif, Mona S
Omar, Anan
Gaafar, Rabab
Zekri, Abdel-Rahman N
Ahmed, Ola S
Bahnassy, Abeer
author_facet Malash, Ibrahim
Mansour, Osman
Shaarawy, Sabry
Abdellateif, Mona S
Omar, Anan
Gaafar, Rabab
Zekri, Abdel-Rahman N
Ahmed, Ola S
Bahnassy, Abeer
author_sort Malash, Ibrahim
collection PubMed
description BACKGROUND: Metastatic breast cancer (MBC) represents a major health problem in Egypt and worldwide. Prognostic and predictive factors for patients with MBC are highly required for better management and improved survival. The aim of this study was to assess the prognostic and predictive value(s) of CYP2D6 polymorphisms in Tamoxifen responders and non-responders. METHODS: A cohort of 157 hormone receptor positive, locally recurrent inoperable and/or metastatic (MBC) Egyptian female patients was assessed for CYP2D6 polymorphisms. Data were correlated to relevant clinic-pathological features of the patients, response to tamoxifen, and survival rates. RESULTS: CYP2D6 polymorphisms were detected in 44/157 cases (28%), 30 of them (68.2%) were refractory and 14 (31.8%) were responders (P=0.027). The CYP2D6 *3,*4 variants were significantly prevalent in the refractory group 26/30 (86.6%), while the *10/*10 and *10/*3 variants were more common in the responders 12/14 (85.71%, P=0.027). CYP2D6 polymorphism associated significantly with Her-2 amplification (P=0.001) as well as reduced overall survival rates in both refractory and responder patients (P< 0.001). CONCLUSION: CYP2D6 polymorphisms can significantly predict response to Tamoxifen treatment, and also associates with poor overall survival rates in MBC patients.
format Online
Article
Text
id pubmed-8046328
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-80463282021-04-16 The Role of CYP2D6 Polymorphisms in Determining Response to Tamoxifen in Metastatic Breast Cancer Patients: Review and Egyptian Experience Malash, Ibrahim Mansour, Osman Shaarawy, Sabry Abdellateif, Mona S Omar, Anan Gaafar, Rabab Zekri, Abdel-Rahman N Ahmed, Ola S Bahnassy, Abeer Asian Pac J Cancer Prev Research Article BACKGROUND: Metastatic breast cancer (MBC) represents a major health problem in Egypt and worldwide. Prognostic and predictive factors for patients with MBC are highly required for better management and improved survival. The aim of this study was to assess the prognostic and predictive value(s) of CYP2D6 polymorphisms in Tamoxifen responders and non-responders. METHODS: A cohort of 157 hormone receptor positive, locally recurrent inoperable and/or metastatic (MBC) Egyptian female patients was assessed for CYP2D6 polymorphisms. Data were correlated to relevant clinic-pathological features of the patients, response to tamoxifen, and survival rates. RESULTS: CYP2D6 polymorphisms were detected in 44/157 cases (28%), 30 of them (68.2%) were refractory and 14 (31.8%) were responders (P=0.027). The CYP2D6 *3,*4 variants were significantly prevalent in the refractory group 26/30 (86.6%), while the *10/*10 and *10/*3 variants were more common in the responders 12/14 (85.71%, P=0.027). CYP2D6 polymorphism associated significantly with Her-2 amplification (P=0.001) as well as reduced overall survival rates in both refractory and responder patients (P< 0.001). CONCLUSION: CYP2D6 polymorphisms can significantly predict response to Tamoxifen treatment, and also associates with poor overall survival rates in MBC patients. West Asia Organization for Cancer Prevention 2020-12 /pmc/articles/PMC8046328/ /pubmed/33369460 http://dx.doi.org/10.31557/APJCP.2020.21.12.3619 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Malash, Ibrahim
Mansour, Osman
Shaarawy, Sabry
Abdellateif, Mona S
Omar, Anan
Gaafar, Rabab
Zekri, Abdel-Rahman N
Ahmed, Ola S
Bahnassy, Abeer
The Role of CYP2D6 Polymorphisms in Determining Response to Tamoxifen in Metastatic Breast Cancer Patients: Review and Egyptian Experience
title The Role of CYP2D6 Polymorphisms in Determining Response to Tamoxifen in Metastatic Breast Cancer Patients: Review and Egyptian Experience
title_full The Role of CYP2D6 Polymorphisms in Determining Response to Tamoxifen in Metastatic Breast Cancer Patients: Review and Egyptian Experience
title_fullStr The Role of CYP2D6 Polymorphisms in Determining Response to Tamoxifen in Metastatic Breast Cancer Patients: Review and Egyptian Experience
title_full_unstemmed The Role of CYP2D6 Polymorphisms in Determining Response to Tamoxifen in Metastatic Breast Cancer Patients: Review and Egyptian Experience
title_short The Role of CYP2D6 Polymorphisms in Determining Response to Tamoxifen in Metastatic Breast Cancer Patients: Review and Egyptian Experience
title_sort role of cyp2d6 polymorphisms in determining response to tamoxifen in metastatic breast cancer patients: review and egyptian experience
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046328/
https://www.ncbi.nlm.nih.gov/pubmed/33369460
http://dx.doi.org/10.31557/APJCP.2020.21.12.3619
work_keys_str_mv AT malashibrahim theroleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience
AT mansourosman theroleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience
AT shaarawysabry theroleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience
AT abdellateifmonas theroleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience
AT omaranan theroleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience
AT gaafarrabab theroleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience
AT zekriabdelrahmann theroleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience
AT ahmedolas theroleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience
AT bahnassyabeer theroleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience
AT malashibrahim roleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience
AT mansourosman roleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience
AT shaarawysabry roleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience
AT abdellateifmonas roleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience
AT omaranan roleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience
AT gaafarrabab roleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience
AT zekriabdelrahmann roleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience
AT ahmedolas roleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience
AT bahnassyabeer roleofcyp2d6polymorphismsindeterminingresponsetotamoxifeninmetastaticbreastcancerpatientsreviewandegyptianexperience